Targeting tauopathy with engineered tau-degrading intrabodies.

Gilbert GallardoConnie H WongSara M RicardezCarolyn N MannKent H LinCheryl E G LeynsHong JiangDavid M Holtzman

Published in: Molecular neurodegeneration (2019)

This study, harnesses the strength of intrabodies that are amendable for targeting specific domains or modifications with the cell-intrinsic mechanisms that regulate protein degradation providing a new immunotherapeutic approach with potentially improved efficacy.

Keyphrases

cancer therapy
single cell
cell therapy
cerebrospinal fluid
protein protein
small molecule